CN101448528A - 白细胞介素-1α免疫诱导预防动脉粥样硬化的自身抗体 - Google Patents

白细胞介素-1α免疫诱导预防动脉粥样硬化的自身抗体 Download PDF

Info

Publication number
CN101448528A
CN101448528A CNA2007800186140A CN200780018614A CN101448528A CN 101448528 A CN101448528 A CN 101448528A CN A2007800186140 A CNA2007800186140 A CN A2007800186140A CN 200780018614 A CN200780018614 A CN 200780018614A CN 101448528 A CN101448528 A CN 101448528A
Authority
CN
China
Prior art keywords
atherosclerosis
disease
mice
mammal
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800186140A
Other languages
English (en)
Chinese (zh)
Inventor
J·赛玛德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XBIOTECH Inc
Original Assignee
XBIOTECH Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XBIOTECH Inc filed Critical XBIOTECH Inc
Publication of CN101448528A publication Critical patent/CN101448528A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Oxide Ceramics (AREA)
CNA2007800186140A 2006-05-15 2007-05-15 白细胞介素-1α免疫诱导预防动脉粥样硬化的自身抗体 Pending CN101448528A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80002906P 2006-05-15 2006-05-15
US60/800,029 2006-05-15

Publications (1)

Publication Number Publication Date
CN101448528A true CN101448528A (zh) 2009-06-03

Family

ID=38694276

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800186140A Pending CN101448528A (zh) 2006-05-15 2007-05-15 白细胞介素-1α免疫诱导预防动脉粥样硬化的自身抗体

Country Status (9)

Country Link
US (1) US20090191149A1 (https=)
EP (1) EP2021033B1 (https=)
JP (1) JP2009537507A (https=)
CN (1) CN101448528A (https=)
AT (1) ATE551365T1 (https=)
AU (1) AU2007251239B2 (https=)
CA (1) CA2652274A1 (https=)
ES (1) ES2384278T3 (https=)
WO (1) WO2007132338A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105175504A (zh) * 2015-09-08 2015-12-23 苏州普罗达生物科技有限公司 血管性血友病因子抑制多肽及其应用
CN105175503A (zh) * 2015-09-08 2015-12-23 苏州普罗达生物科技有限公司 因子viii抑制多肽及其应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617637C (en) * 2005-08-02 2017-07-18 Xbiotech Inc. Diagnosis, treatment, and prevention of vascular disorders using il-1.alpha. autoantibodies
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
US20100040574A1 (en) * 2006-05-22 2010-02-18 Xbiotech Inc. TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIES
EP2285409B1 (en) 2008-05-30 2016-04-20 XBiotech, Inc Il-1 alpha antibodies
CA2737056C (en) * 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes
EP2569640A1 (en) 2010-05-12 2013-03-20 The University of Birmingham Biomarker
EP2582391B1 (en) 2010-06-18 2018-10-03 XBiotech, Inc Arthritis treatment
KR101910760B1 (ko) 2010-08-23 2018-10-22 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN108404127B (zh) 2011-09-23 2025-12-12 埃克斯生物科技公司 恶病质治疗
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
JP6456015B2 (ja) * 2013-07-19 2019-01-23 国立大学法人三重大学 閉塞性動脈硬化症モデル動物、るい痩研究用モデル動物、及び全身性アミロイドーシスモデル動物としての非ヒト哺乳動物
EP3582813A4 (en) 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802402D0 (sv) * 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US6555579B2 (en) * 1998-08-13 2003-04-29 The Wistar Institute Methods for reducing atherosclerotic plaques
US20030040617A9 (en) * 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030232054A1 (en) * 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CA2617637C (en) 2005-08-02 2017-07-18 Xbiotech Inc. Diagnosis, treatment, and prevention of vascular disorders using il-1.alpha. autoantibodies
NZ566971A (en) * 2005-09-28 2011-06-30 Cytos Biotechnology Ag Vaccine containing a virus like particle linked with an interleukin-1 molecule
EP2285409B1 (en) * 2008-05-30 2016-04-20 XBiotech, Inc Il-1 alpha antibodies
CA2737056C (en) * 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAN H.VON DER THUSEN ET AL: "Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential", 《PHARMACOLOGICAL REVIEWS》 *
M.SVENSON ET AL: "Distribution and Characterization of Autoantibodies to Interleukin lα in Normal Human Sera", 《SCAND.J.IMMUNOL.》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105175504A (zh) * 2015-09-08 2015-12-23 苏州普罗达生物科技有限公司 血管性血友病因子抑制多肽及其应用
CN105175503A (zh) * 2015-09-08 2015-12-23 苏州普罗达生物科技有限公司 因子viii抑制多肽及其应用

Also Published As

Publication number Publication date
AU2007251239A1 (en) 2007-11-22
ES2384278T3 (es) 2012-07-03
WO2007132338A3 (en) 2008-06-12
JP2009537507A (ja) 2009-10-29
EP2021033B1 (en) 2012-03-28
CA2652274A1 (en) 2007-11-22
US20090191149A1 (en) 2009-07-30
EP2021033A2 (en) 2009-02-11
EP2021033A4 (en) 2010-02-24
WO2007132338A2 (en) 2007-11-22
ATE551365T1 (de) 2012-04-15
AU2007251239B2 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
CN101448528A (zh) 白细胞介素-1α免疫诱导预防动脉粥样硬化的自身抗体
US20120114598A1 (en) IL-1alpha immunization induces autoantibodies protective against atherosclerosis
Lima et al. Eosinophilic inflammation and airway hyper‐responsiveness are profoundly inhibited by a helminth (Ascaris suum) extract in a murine model of asthma
Sonderegger et al. Neutralization of IL‐17 by active vaccination inhibits IL‐23‐dependent autoimmune myocarditis
Akdis et al. Mechanisms of allergen-specific immunotherapy
Matthys et al. Anti‐IL‐12 antibody prevents the development and progression of collagen‐induced arthritis in IFN‐γ receptor‐deficient mice
Okiyama et al. Therapeutic effects of interleukin‐6 blockade in a murine model of polymyositis that does not require interleukin‐17A
Driss et al. The schistosome glutathione S-transferase P28GST, a unique helminth protein, prevents intestinal inflammation in experimental colitis through a Th2-type response with mucosal eosinophils
Wu et al. Pathogenic IL‐23 signaling is required to initiate GM‐CSF‐driven autoimmune myocarditis in mice
CN102256620B (zh) 用于治疗阿尔茨海默氏病的免疫治疗组合物
Katz et al. Erythropoietin enhances immune responses in mice
JP6955324B2 (ja) 医薬化合物を評価するための新規動物モデル
PT2109623E (pt) Tratamento de cancro com anticorpos anti-il-1
Ochs et al. Complement, membrane glycoproteins, and complement receptors: their role in regulation of the immune response
Mishra et al. Peyer's patch eosinophils: identification, characterization, and regulation by mucosal allergen exposure, interleukin-5, and eotaxin
Constantinescu et al. Modulation of susceptibility and resistance to an autoimmune model of multiple sclerosis in prototypically susceptible and resistant strains by neutralization of interleukin-12 and interleukin-4, respectively
Thelemann et al. Absence of nonhematopoietic MHC class II expression protects mice from experimental autoimmune myocarditis
Guan et al. Targeting IL-12/IL-23 by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis
US20140227304A1 (en) Vaccines for preventing and treating alzheimer's disease
Zaringhalam et al. Relationship between serum IL10 level and p38MAPK enzyme activity on behavioral and cellular aspects of variation of hyperalgesia during different stages of arthritis in rats
Babai et al. Depletion of peritoneal CD5+ B cells has no effect on the course of Leishmania major infection in susceptible and resistant mice
Sheldrake et al. Immune defences at mucosal surfaces in ruminants
Hainline et al. Active immunotherapy for C5a-mediated inflammation using adjuvant-free self-assembled peptide nanofibers
US9173928B2 (en) DNA vaccine for Alzheimer's disease
WO2020096046A1 (ja) 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090603